Dr. Alberts is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Steven R. Alberts, M.D., is a professor of oncology in the College of Medicine, Mayo Clinic, and a consultant in the Division of Medical Oncology. He has served as the chair of the Division of Medical Oncology since 2012 and has been interim chair of the Department of Oncology since 2019. He is also the Deputy Director for Clinical Research in the Mayo Clinic Cancer Center. External to Mayo Clinic Dr. Alberts serves as a member of the Board of Directors and the Board of Trustees for the Alliance.
Dr. Alberts has a clinical focus in gastrointestinal cancers and a specific interest in liver-based cancers and in pancreatic cancer.
Dr. Alberts has a long-standing research career that predates his appointment in medical oncology. He has a master's in public health and has worked as an epidemiologist with the Indian Health Service and the Centers for Disease Control and Prevention. In this former position, Dr. Alberts participated in studies of cancer in the Alaska Native population.
Dr. Alberts previously served as the chair of the GI Committee for the North Central Cancer Treatment Group. He also served as a member of the National Cancer Institute-sponsored Gastrointestinal Intergroup GI Steering Committee, Pancreas Cancer Task Force, and Colon Cancer Task Force to help coordinate clinical trials through the national cooperative groups.
Education & Training
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1993 - 1997
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1990 - 1993
- University of Washington School of MedicineClass of 1990
Certifications & Licensure
- MN State Medical License 1991 - 2025
- WI State Medical License 2023 - 2025
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Start of enrollment: 1994 Jul 01
- Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer Start of enrollment: 1998 Mar 01
- Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer Start of enrollment: 1999 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 471 citationsNeoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection ratesGunnar Folprecht, Axel Grothey, Steven R. Alberts, Hans-Rudolf Raab, C.-H. Köhne
Annals of Oncology. 2005-08-01 - 378 citationsOxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II ...Steven R. Alberts, William L. Horvath, William C. Sternfeld, Richard M. Goldberg, Michelle R. Mahoney
Journal of Clinical Oncology. 2005-12-20 - 1804 citationsA Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal CancerRichard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, Ramesh K. Ramanathan
Journal of Clinical Oncology. 2004-01-01
Journal Articles
- MiR-139-5p as a Novel Serum Biomarker for Recurrence and Metastasis in Colorectal CancerFrank A Sinicrope, Steven R Alberts, Ajay Goel, Nature
Press Mentions
- Sharing Mayo Clinic: Georgia Man with Neuroendocrine Cancer Gains Quality of Life Thanks to New Nuclear Med TherapyApril 17th, 2022
- Georgia Man with Neuroendocrine Cancer Gains Quality of Life Thanks to New Nuclear Med TherapyApril 14th, 2022
- Therapeutic Advancements Changing Liver Cancer ParadigmSeptember 25th, 2017
- Join now to see all
Grant Support
- NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1.National Cancer Institute.2019–2025
- Mayo Clinic Hepatobiliary SPORENational Cancer Institute2018–2023
- Minnesota Cancer Clinical Trials Network Regional Cancer Clinical Trials Funding OpportunityState of Minnesota2018–2020
- Clinical ResearchNational Cancer Institute2009–2012
- Core--Protocol Review And Monitoring SystemNational Cancer Institute2004–2008
- Phase II Trial Of Gemcitabine And DocetaxelNational Center For Research Resources2004
- BAY 12 9566 In Combination W/ Etoposide &Carboplatin In Cancer PatientsNational Center For Research Resources1999–2002
- Phase 2 Clinical Trial Of An Antiandrogen &A 5-AlphaDivision Of Cancer Prevention And Control1999
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: